2019-nCoV Nucleocapsid Recombinant Antigen, full length (Ag-8) - High-quality Detection and Diagnosis Tool
ProcurenetShort description
- Recombinant antigen expressed in E. coli: Produced using advanced genetic engineering techniques to ensure the highest purity and quality.
- Suitable for lateral flow assay: Specifically designed for use in lateral flow assays, providing rapid and accurate detection of 2019-nCoV.
- Synonyms: SARS-CoV, SARS-CoV-2: Also known as SARS-CoV and SARS-CoV-2, covering a wide range of coronavirus strains.
- Essential for accurate detection and diagnosis of 2019-nCoV: Integral in identifying and confirming the presence of the 2019-nCoV virus, aiding in swift and effective medical response.
- Comprehensive MSDS available: Detailed Material Safety Data Sheet included, ensuring compliance with safety regulations and guidelines.
- Supported by peer-reviewed papers and technical documents: Backed by scientific literature and technical research, validating the performance and reliability of the antigen.
- Long shelf life: Provides extended usability and convenience for multiple testing needs.
- Highly sensitive and specific: Ensures accurate and reliable detection results for efficient diagnosis and monitoring.
-
Procurenet Team Tshim Sha Tsui
Hong Kong
3 years
Description
2019-nCoV Nucleocapsid Recombinant Antigen, full length (Ag-8) - High-quality Detection and Diagnosis Tool
Introducing the 2019-nCoV Nucleocapsid Recombinant Antigen, full length (Ag-8), a highly reliable and top-quality product crucial for accurate detection and diagnosis of 2019-nCoV. This recombinant antigen is expressed in E. coli, ensuring its consistent and efficient production. It is specifically designed for use in lateral flow assays and has a wide range of applications in various research and clinical settings.
Composition:
- The 2019-nCoV Nucleocapsid Recombinant Antigen, full length (Ag-8) is carefully manufactured using advanced recombinant DNA technology. It is produced by expressing the nucleocapsid protein of the 2019-nCoV virus in E. coli. This process ensures high purity and quality, enabling accurate and reliable results in diagnostic assays. The antigen is formulated and optimized to ensure excellent stability and consistency, facilitating its use in a wide range of applications.
Key Features:
- Recombinant antigen expressed in E. coli: The 2019-nCoV Nucleocapsid Recombinant Antigen, full length (Ag-8) is produced in E. coli, allowing for efficient and reliable expression of the target protein. This ensures consistent production and high yield, making it an ideal choice for large-scale manufacturing.
- Suitable for lateral flow assay: This recombinant antigen is specifically designed for use in lateral flow assays. It exhibits excellent binding affinity to antibodies and provides accurate and sensitive detection of 2019-nCoV. Its compatibility with lateral flow assays makes it a valuable tool for rapid and point-of-care diagnostics.
- Synonyms: SARS-CoV, SARS-CoV-2: The 2019-nCoV Nucleocapsid Recombinant Antigen, full length (Ag-8) is also known by its synonyms, SARS-CoV and SARS-CoV-2. This makes it compatible with existing research and diagnostic protocols targeting these related viruses.
- High quality and purity: With a focus on quality, the 2019-nCoV Nucleocapsid Recombinant Antigen, full length (Ag-8) undergoes rigorous quality control procedures to ensure its purity and integrity. It is extensively tested for contaminants and impurities to guarantee reliable and reproducible results.
- Essential for accurate detection and diagnosis of 2019-nCoV: The presence of the 2019-nCoV Nucleocapsid Recombinant Antigen, full length (Ag-8) is crucial for accurate detection and diagnosis of 2019-nCoV. Its highly specific and reliable performance enables healthcare professionals and researchers to confidently identify and monitor the presence of the virus.
- Comprehensive MSDS available: For your convenience and safety, a comprehensive Material Safety Data Sheet (MSDS) is available for the 2019-nCoV Nucleocapsid Recombinant Antigen, full length (Ag-8). This document provides detailed information on the handling, storage, and disposal of the antigen, ensuring its safe and responsible use.
- Supported by peer-reviewed papers and technical documents: The 2019-nCoV Nucleocapsid Recombinant Antigen, full length (Ag-8) is backed by extensive scientific research and technical documentation. Peer-reviewed papers and technical documents provide evidence of its efficacy, reliability, and performance, helping to facilitate confident and accurate detection and diagnosis of 2019-nCoV.
Find similar products and more at AGX808:
If you're looking for additional products or related items, visit AGX808, our comprehensive catalog of high-quality reagents, antibodies, and equipment for molecular and cellular biology research. Explore our vast collection and discover valuable tools to advance your research and diagnostic efforts.
